Core Viewpoint - Four Ring Pharmaceutical's subsidiary, Huisheng Biopharmaceutical, has received drug registration approval from the National Medical Products Administration of China for Dapagliflozin tablets, marking it as the first SGLT-2 inhibitor approved for market in the world [1][2] Company Summary - Dapagliflozin tablets are a new oral hypoglycemic drug for type 2 diabetes, which selectively inhibit the SGLT-2 receptor in the renal proximal tubule, reducing glucose reabsorption and promoting urinary glucose excretion [1] - The approval of Dapagliflozin tablets enhances the product portfolio of Four Ring Pharmaceutical and Huisheng Biopharmaceutical in the diabetes treatment sector, providing better treatment options for patients [2] Industry Summary - According to the International Diabetes Federation, there were 537 million adults with diabetes globally in 2021, with a prevalence rate of 10.5%, and China accounted for 141 million patients, or 26.2% of the global total [2] - The market for SGLT-2 inhibitors is rapidly growing, with projected sales in mainland China nearing 8 billion yuan in the first three quarters of 2024, and Dapagliflozin's sales expected to reach approximately 7 billion yuan [2] - Industry experts indicate that Dapagliflozin is maintaining an annual growth rate of 20% to 30% [2]
四环医药(00460)：惠升生物研发的达格列净片获国家药监局上市批准